Haemonetics Corporation Common Stock (NY:HAE)

119.92 +1.60 (+1.35%)

Delayed Quote Updated: 2:41 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Haemonetics Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Incyte, Haemonetics Post Earnings Beats; One Surges Within Buy Zone ↗

February 07, 2023

Haemonetics stock rose within a buy zone on Tuesday, but Incyte stock toppled.

Via Investor's Business Daily

Earnings Preview: Haemonetics ↗

February 06, 2023

Via Benzinga

Where Haemonetics Stands With Analysts ↗

January 24, 2023

Via Benzinga

How 2022's Biggest Healthcare Gainers Could Fare In 2023

January 06, 2023

Health care stocks were hit hard early in the pandemic but these three have made quite a comeback. This article examines where they could go in 2023

Via MarketBeat

9 Analysts Have This to Say About Haemonetics ↗

December 12, 2022

Via Benzinga

InMode Stock Shows Improved Technical Strength; Hits Key Technical Threshold ↗

November 16, 2022

The Relative Strength (RS) Rating for InMode stock moved up into a higher percentile Wednesday, as it got a lift from 64 to 78.

Via Investor's Business Daily

Analysts Take Bullish Stance On Haemonetics, Cites Plasma Momentum As Catalyst ↗

November 08, 2022

Via Benzinga

Watch for Continued Gains in Shares of Haemonetics Corporation (HAE)

September 12, 2022

Via Investor Brand Network

Where Haemonetics Stands With Analysts ↗

August 11, 2022

Within the last quarter, Haemonetics (NYSE:HAE) has observed the following analyst ratings:

Via Benzinga

Haemonetics: Q1 Earnings Insights ↗

August 10, 2022

Haemonetics (NYSE:HAE) reported its Q1 earnings results on Wednesday, August 10, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

December 01, 2022

During Thursday's session, 108 stocks hit new 52-week highs.

Via Benzinga

Haemonetics: Q2 Earnings Insights ↗

November 07, 2022

Haemonetics (NYSE:HAE) reported its Q2 earnings results on Monday, November 7, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings Haemonetics beat estimated earnings...

Via Benzinga

Expert Ratings for Haemonetics ↗

October 13, 2022

Over the past 3 months, 6 analysts have published their opinion on Haemonetics (NYSE:HAE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022 ↗

October 13, 2022

Upgrades

Via Benzinga

Haemonetics Stock Near Buy Zone With EPS Due ↗

July 27, 2022

With its next earnings report scheduled for around Aug. 10, Haemonetics stock is trading about 10% shy of a 75.44 buy point.

Via Investor's Business Daily

Leading Medical Stocks, Including Sensus And Shockwave, Have Grown At Least 36% This Year ↗

October 05, 2022

Biotech isn't the only place to make money in health care this year.

Via Investor's Business Daily

Cutera Stock Earns Relative Strength Rating Upgrade ↗

October 03, 2022

On Monday, medical aesthetic Cutera stock had its Relative Strength (RS) Rating upgraded to 90 from 80 a day earlier.

Via Investor's Business Daily

Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary ↗

September 12, 2022

Via Benzinga

Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review ↗

August 12, 2022

The major indexes continued to advance, despite some key warnings.

Via Investor's Business Daily

Raymond James Thinks Haemonetics Growth Is 'Underappreciated' ↗

July 01, 2022

Via Benzinga

Haemonetics: Q4 Earnings Insights ↗

May 10, 2022

Haemonetics (NYSE:HAE) reported its Q4 earnings results on Tuesday, May 10, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Haemonetics Surges Closer To A Breakout After Squashing Quarterly Estimates, Raising Guidance ↗

August 10, 2022

The blood and plasma supplies provider also raised its sales guidance for the fiscal year.

Via Investor's Business Daily

InMode Stock Scores Relative Strength Rating Upgrade; Hits Key Threshold ↗

August 09, 2022

On Tuesday, InMode stock got a positive adjustment to its Relative Strength (RS) Rating, to 86 from 72 a day earlier.

Via Investor's Business Daily

ShockWave Medical Stock Scores Rising Price Performance With Jump To 92 RS Rating ↗

July 11, 2022

ShockWave Medical stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an increase from 81 to 92.

Via Investor's Business Daily

Morgan Stanley Maintains Equal-Weight Rating for Haemonetics: Here's What You Need To Know ↗

July 01, 2022

Morgan Stanley has decided to maintain its Equal-Weight rating of Haemonetics (NYSE:HAE) and raise its price target from $60.00 to $70.00. Shares of Haemonetics are trading up 1.46% over the last 24...

Via Benzinga

4 Analysts Have This to Say About Haemonetics ↗

July 01, 2022

Over the past 3 months, 4 analysts have published their opinion on Haemonetics (NYSE:HAE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

Needham Sees Reasonable Forecasts For Haemonetics, With Some Tailwinds ↗

June 15, 2022

Haemonetics Corporation's (NYSE: HAE) analyst day later this month may include an update on its businesses, new products, margin outlook, and financial targets for FY24-FY26.

Via Benzinga

ShockWave Medical Stock Shows Rising Price Performance With Jump To 91 RS Rating ↗

June 13, 2022

On Monday, ShockWave Medical stock received an upgrade to its Relative Strength (RS) Rating, from 86 to 91.

Via Investor's Business Daily

77 Stocks Moving In Tuesday's Mid-Day Session ↗

May 10, 2022

Gainers

Via Benzinga

103 Biggest Movers From Yesterday ↗

May 11, 2022

Gainers

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.